GSK-2181236A
GSK-2181236A is a pharmaceutical compound developed by GlaxoSmithKline (GSK) for the treatment of various medical conditions. It is a small molecule inhibitor that targets specific pathways involved in disease processes. This article provides a comprehensive overview of GSK-2181236A, including its mechanism of action, clinical applications, pharmacokinetics, and ongoing research.
Mechanism of Action[edit | edit source]
GSK-2181236A functions as a selective inhibitor of the enzyme phosphoinositide 3-kinase (PI3K). PI3K is a critical component of the PI3K/AKT/mTOR signaling pathway, which is involved in cell growth, proliferation, and survival. By inhibiting PI3K, GSK-2181236A disrupts this pathway, leading to reduced tumor cell growth and increased apoptosis in cancer cells.
Clinical Applications[edit | edit source]
GSK-2181236A is primarily investigated for its potential use in oncology. It has shown promise in the treatment of various types of cancer, including:
In addition to its use in cancer therapy, GSK-2181236A is being explored for its potential benefits in treating inflammatory diseases due to its ability to modulate immune responses.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of GSK-2181236A includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. It is administered orally and has a bioavailability that allows for effective systemic exposure. The compound is metabolized primarily in the liver and excreted via the renal and biliary systems.
Ongoing Research[edit | edit source]
Research on GSK-2181236A is ongoing, with numerous clinical trials evaluating its efficacy and safety in different patient populations. Studies are also investigating its potential synergistic effects when used in combination with other therapeutic agents, such as chemotherapy and immunotherapy.
Safety and Side Effects[edit | edit source]
As with many targeted therapies, GSK-2181236A may cause side effects, which can include:
- Gastrointestinal disturbances
- Fatigue
- Skin rash
- Elevated liver enzymes
Patients receiving GSK-2181236A are monitored closely for these adverse effects, and dose adjustments may be necessary to manage toxicity.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
